ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
February 18, 2025InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China. -
Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
December 10, 2024Ascentage Pharma (6855.HK) today announced that it has released the latest clinical data of lisaftoclax (APG-2575) as a monotherapy or in combinations in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Pharma Sources Insight January 2025
